The Sound of Evolution
Ziprasidone
Mechanism of action:
Ziprasidone has multiple receptor-modulating properties. It blocks dopamine D₂ receptors in the central nervous system, particularly within the mesolimbic pathway, thereby reducing positive symptoms caused by excessive dopamine activity. Ziprasidone also antagonizes 5-HT₂A receptors, which helps alleviate some negative symptoms and lowers the risk of extrapyramidal symptoms (EPS). In addition, it inhibits the serotonin transporter and the norepinephrine transporter, increasing the synaptic concentrations of serotonin (5-HT) and norepinephrine and thereby enhancing their effects.
Reference(s):
1. Stahl SM et al. (2003). The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry.
2. Schmidt AW et al. (2001). Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol.
3. Beedham C et al. (2003). Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol.